NCT03791034 Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
| NCT ID | NCT03791034 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | Non-small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2017-08-28 |
| Primary Completion | 2021-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2017-08-28 with a primary completion date of 2021-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
Eligibility Criteria
Inclusion Criteria: * All subjects need to sign the informed consent form * All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively. * Non-small cell lung cancer have to confirmed pathologically after operation * Clinical stage I - IIIA by AJCC 7th staging system Exclusion Criteria: * Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer * Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment * Recurrent lung cancer * Stage IIIB, IV by AJCC 7th staging system
Contact & Investigator
Jhingook Kim, MD
STUDY CHAIR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT03791034 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Non-small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03791034 currently recruiting?
Yes, NCT03791034 is actively recruiting participants. Contact the research team at jkimsmc@skku.edu for enrollment information.
Where is the NCT03791034 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT03791034 clinical trial?
NCT03791034 is sponsored by Samsung Medical Center. The principal investigator is Jhingook Kim, MD at Samsung Medical Center. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.